Martin Winn

A new nasal decongestant, A-57219: a comparison with oxymetazoline

2‐(4‐Amino‐3,5‐dichlorobenzyl)imidazolin hydrochloride (A‐57219), has α1‐agonist/α2‐antagonist activity and was more effective and long‐acting than oxymetazoline on canine nasal mucosa, in‐vitro and in‐vivo. Upon intranasal administration to dogs, the compound was devoid of systemic effects up to a concentration 1000 times that needed for local decongestant effect (1ṁ65 μg, atomized from a 1 μg mL‐1 solution) suggesting limited mucosal absorption. After nasal administration to rats for 15 days at a concentration 1000 times greater than that required for nasal decongestion, no mucosal tissue toxicity or systemic effects were seen.